Clinical MilestonesThe company plans to achieve human in vivo proof of concept for at least one indication, showing progress toward clinical milestones.
Research And DevelopmentEDIT plans to declare two in vivo development candidates for HSC and liver editing, demonstrating proactive steps in R&D.
Therapeutic OutcomesEDIT's LNP formulation optimization resulted in significant increases in gene editing efficiency in mouse HSPCs, indicating potential for improved therapeutic outcomes.